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ABSTRACT
Background: 30―80% of outgrown asthma subjects develop symptoms again later in life. We investigated in-
flammation and function of lower airway in adolescents with former asthma.
Methods: 326 never-smoking young adults (mean age 24.0 years) were interviewed with special emphasis on
history of asthma. Diagnosis of asthma was based on GINA guidelines. Former asthma subjects consisted of
ones with a history of physician-diagnosed childhood asthma, who had been free of asthma symptoms without
the use of medication for at least 10 years prior to the study. Provocative concentration of methacholine caus-
ing a 20% fall in forced expiratory volume in 1 second (FEV1) (PC20) and eosinophil percentage in induced spu-
tum were measured.
Results: 31 subjects were former asthma subjects (FBA), 11 subjects were current asthma subjects (CBA)
and 284 subjects had no history of asthma (non-BA). PC20 and FEV1FVC ratio were significantly lower in the
FBA group than in the non-BA group (P < 0.01). Maximal mid-expiratory flow (MMF) was significantly lower in
the FBA group than in the non-BA group (P < 0.05). Sputum eosinophil percentage was significantly increased
in the FBA group compared with the non-BA group (P < 0.01). PC20 was significantly lower in the CBA group
than in the FBA and non-BA groups (P < 0.01). FEV1, FEV1FVC ratio and MMF were significantly lower in the
CBA group than in the FBA group (P < 0.05, P < 0.05 and P < 0.05, respectively) and the non-BA group (P <
0.01, P < 0.01 and P < 0.05, respectively). Sputum eosinophils were significantly higher in the CBA group than
in the FBA and non-BA groups (P < 0.01).
Conclusions: This study shows that subjects with long-term outgrown asthma continue to have airway
eosinophilic inflammation, airway hyperresponsiveness and airway narrowing.
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INTRODUCTION
Asthma is a clinical entity characterized by a combi-
nation of three features: airway obstruction with
spontaneous andor pharmacological reversibility, in-
creased bronchial responsiveness, and airway inflam-
mation. Airway inflammation has been considered
the primary event leading to airway obstruction and
hyperresponsiveness.1
Epidemiologic studies demonstrated that a consid-
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erable proportion of children with asthma in remis-
sion develop symptoms again later in life.2 It has also
been shown that eosinophilic airway inflammation is
present in outgrown asthma children3 and adult
atopic asthma subjects4 in clinical remission. Further-
more, most adults with former asthma considered in
remission showed a persistent increase in airway re-
sponsiveness to methacholine5,6 and airway remodel-
ing was present during clinical remission of atopic
asthma subjects.4 Some authors have suggested that
ongoing airway inflammation is the principal cause of
progressive airway abnormalities7 and, consequently,
high relapse rate.3,4
To our knowledge, in most previous studies except
one,8 clinical remission of asthma was defined as re-
ported complete absence of asthma symptoms in sub-
jects not taking any asthma medication for only a few
years. We examined the inflammation and function of
the lower airways in young adults who had been free
of symptoms and had not taken any asthma medica-
tions for at least 10 years before the study.
METHODS
SUBJECTS
This study was performed between 2002 and 2005. A
total of 326 never-smoking students of Kanazawa Uni-
versity School of Medicine, aged 21 to 34 years
(mean age 24.0 years), were interviewed with special
emphasis on history of asthma. Diagnosis of asthma
was based on GINA guidelines.9 Current asthma sub-
jects consisted of students with asthma symptoms
within the previous year, who had taken no asthma
medications for at least 4 weeks before or during the
study period. Former asthma subjects consisted of
students with history of physician-diagnosed child-
hood asthma, who had been free of asthma symp-
toms and had not taken any asthma medication for at
least 10 years prior to the study. No subject had a his-
tory of respiratory infections for at least 4 weeks be-
fore or during the study period. The study was ap-
proved by the Ethics Committee of Kanazawa Univer-
sity, and informed consent was obtained from all sub-
jects after the purpose of the test had been explained.
STUDY DESIGN
Pulmonary function, the methacholine concentration
producing a 20% fall in forced expiratory volume in 1
second (FEV1) (PC20) and eosinophil percentage in
hypertonic saline-induced sputum were measured
within 3 weeks in random order. The baseline of the
pulmonary function test was measured after physi-
ological saline inhalation during the methacholine
provocation test. The predicted value of FVC, FEV1
and MMF were calculated according to the Japanese
Respiratory Society guidelines.10
MEASUREMENT OF BRONCHIAL RESPONSIVE-
NESS
The methacholine provocation test was done accord-
ing to a previously published method.11 Meth-
acholine chloride was dissolved in physiological sa-
line solution to make concentrations of 0.04, 0.08,
0.16, 0.31, 0.63, 1.25, 2.5, 5, 10, 20, 40, 80 and 160 mg
ml. Saline and each methacholine solution were in-
haled from a DeVilbiss 646 nebulizer (DeVilbiss Co.,
Somerset, PA, USA) operated by compressed air at 5
Lmin. The nebulizer output was 0.14 mlmin. Saline
was inhaled first for 2 minutes and partial and full
flow-volume curves were measured on a dry wedge
spirometer (Chestac 11, Chest Co., Ltd., Tokyo, Ja-
pan). If the change in FEV1 from the baseline value
was 10% or less, inhalation of methacholine was
started, and if the saline solution caused a change in
FEV1 >10%, the test was stopped or postponed. Meth-
acholine was inhaled for 2 minutes by tidal mouth
breathing with the subjects wearing a nose clip, and
this was followed immediately by three measure-
ments of partial and full flow-volume curves at 1-min
intervals; the curve with the largest FVC was retained
for analysis. Increasing concentrations of meth-
acholine were inhaled until a decrease of 20% or more
in FEV1 occurred. PC20 was calculated. When a 20%
or greater fall in FEV1 was not obtained by the final
concentration of methacholine (160 mgml), the PC20
value was assumed to be 320 mgml for statistical
analysis.
SPUTUM INDUCTION
Induction of sputum was done according to a method
described previously by us.12 Hypertonic saline (5%)
was nebulized with a compressor nebulizer (Omron,
Mie, Japan) for 60 minutes. When subjects felt stick-
ing in the throat, they were asked to try to cough spu-
tum into a Petri dish. By this procedure most subjects
successfully produced sputum. Subjects who had not
been able to bring up material at the end of a 60-
minute period were released. The specimens were
considered adequate if alveolar macrophages were
detected and the percentage of squamous cells was
less than 10% among nucleated cells. Sputum was
transferred to slides in small amounts and finely dis-
tributed over two microscopic slides and smeared.
Each smear was air-dried and stained by the May-
Grunwald-Giemsa method. Differential cell counts
were performed by an observer blinded to the clinical
characteristics of the subjects.
DATA ANALYSIS
Data except for PC20 were shown as means ± stan-
dard deviation (SD). PC20 values were expressed as
geometric means with the geometric standard error
of the mean (GSEM) expressed as a factor. Differ-
ences in spirometric values between groups were
analyzed by parametric one-way analysis of variance
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Table 1 Characteristics of subjects
CBAFBANon-BA
1131284Number of 
subjects
23.9±1.523.3±1.1＊＊24.2±2.2Age (years)
6/525/6204/80Sex (M/F)
 170±9.8171±7.2　 168±8.3Height (cm)
63.7±11 65.0±9.3＊＊60.0±9.7Body weight 
(kg)
22.1±3.322.1±2.6＊　21.0±2.3Body mass 
index
Non-BA: non-asthma subjects, FBA: former asthma subjects, 
CBA: curent asthma subjects. Data are expressed as means ± 
SD. ＊P＜0.01 vs. non-BA, ＊＊P＜0.05 vs. non-BA.
Table 2 Pulmonary function and methacholine bronchial 
responsiveness (PC20)
CBAFBANon-BA
 114±14.1 117±21.0112±13.4FVC
(% predicted)
89.9±11.5＊＃＃99.6±14.9101±11.4FEV1
(% predicted)
78.8±9.18＊＃＃83.6±5.92＊88.4±6.45FEV1/FVC 
(%)
74.4±17.9＊＃＃90.9±24.4＊＊99.7±20.8MMF
(% predicted)
0.69 (1.52)＊＃8.71 (1.39)＊41.7 (1.10)PC20 (mg/ml)
Non-BA: non-asthma subjects, FBA: former asthma subjects, 
CBA: curent asthma subjects. Abbreviations: FVC, forced vital 
capacity; FEV1, forced expiratory volume in 1 second; MMF, maxi-
mum mid-expiratory flow; PC20, provocative concentration of 
methacholine causing a 20% fal in FEV1. Data are expressed as 
means (±SD) except for PC20, which is expressed as the geomet-
ric mean value with geometric standard eror of the mean in 
parentheses. ＊P＜0.01 vs. non-BA, #P＜0.01 vs. FBA, ＊＊P＜
0.05 vs. non-BA, ##P＜0.05 vs. FBA.
(ANOVA). Differences in PC20 between groups were
analyzed by ANOVA using logarithmically trans-
formed values. Differences in sputum eosinophils
were analyzed by Mann-Whitney’s U test. X2 tests
were used to make between-group comparison on the
prevalence of successful sputum induction. Correla-
tions between variables were analyzed using the
Spearman’s correlation coefficient. Gender difference
was determined by X2 tests. A P-value of < 0.05 was
taken to indicate significant differences.
RESULTS
SUBJECT CHARACTERISTICS
Based on the interview, 326 non-smoking subjects
were divided into three groups; current asthma sub-
jects (CBA) (n = 11), former asthma subjects (FBA)
(n = 31), non-asthma subjects (non-BA) (n = 284). A
summary of characteristics of subjects is given in Ta-
ble 1. FBA subjects were significantly lower aged
than non-BA subjects (P < 0.05). FBA subjects had a
significantly higher body weight (P < 0.01) and
higher BMI than non-BA subjects (P < 0.05).
PULMONARY FUNCTION TESTS
As shown in Table 2, no difference in FVC was detect-
able between the three groups. CBA subjects had a
significantly lower FEV1 compared with FBA (P <
0.05) and non-BA subjects (P < 0.01). FBA subjects
had a significantly lower FEV1FVC ratio (P < 0.01)
and lower maximum mid-expiratory flow (MMF) (P <
0.05) compared with non-BA subjects. CBA subjects
had a significantly lower FEV1FVC ratio compared
with FBA (P < 0.05) and non-BA subjects (P < 0.01).
CBA subjects had a significantly lower MMF com-
pared with FBA (P < 0.05) and non-BA subjects (P <
0.01).
BRONCHIAL RESPONSIVENESS TO METH-
ACHOLINE
FBA subjects had a significantly lower PC20 com-
pared with non-BA subjects (P < 0.01). CBA subjects
had a significantly lower PC20 compared with both
FBA and non-BA subjects (P < 0.01) (Table 2). One
subject in the CBA group had normal bronchial re-
sponsiveness (PC20 18.8 mgmL). 11 subjects in the
FBA group had normal bronchial responsiveness
(PC20: range 12.2―320 mgmL). 224 subjects in the
non-BA group had normal bronchial responsiveness
(PC20 >10 mgmL).
INDUCED SPUTUM EOSINOPHILS
Sputum eosinophils were significantly greater in FBA
subjects (median: 1.0%, range: 0.0―20.5%) than in non-
BA subjects (median: 0.0%, range: 0.0―12.3%) (P <
0.01). The sputum eosinophil percentage of CBA sub-
jects (median: 4.45%, range: 0.0―31.3%) was signifi-
cantly higher than that of non-BA subjects (P < 0.01)
but not than that of FBA subjects (Fig. 1). There was
no significant difference in prevalence of successful
sputum induction among groups.
8 of 31 FBA subjects (25.8%) had whole normal pul-
monary function (%FVC >80%, FEV1FVC ratio >70%),
normal bronchial responsiveness to methacholine
(PC20 >10 mgmL) and normal sputum eosinophils
(sputum eosinophil percentage <2.5%). 11 CBA sub-
jects had an abnormality either in pulmonary func-
tion, bronchial responsiveness andor sputum eosino-
phils.
RELATIONSHIP BETWEEN SPUTUM EOSINO-
PHILS AND BRONCHIAL RESPONSIVENESS
In 326 subjects, we examined the correlation between
sputum eosinophil percentage and log PC20. The cor-
relation between log PC20 and percentage of sputum
eosinophil was significant (r = −0.310, P < 0.01) (data
Hara J et al.
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Fig. 1 Diferences in eosinophil percentage in hypertonic 
saline-induced sputum among former asthma subjects, cur-
rent asthma subjects and non-asthma subjects (Mann-Whit-
ney U test) Horizontal bars indicate median values. The 
median values of percentages of eosinophils were 0.0% in 
non-BA, 1.0% in FBA and 4.45% in CBA subjects.
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Fig. 2A Corelation between eosinophil percentage in hy-
pertonic saline-induced sputum and log PC20 in former and 
curent asthma subjects. r; Spearman’s rank corelation 
coeficient.
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Fig. 2B Corelation between eosinophil percentage in hy-
pertonic saline-induced sputum and log PC20 in non-asthma 
subjects. r; Spearman’s rank corelation coeficient.
not shown). In 42 CBA and FBA subjects, there was
significant correlation between log PC20 and percent-
age of sputum eosinophils (r = −0.396, P < 0.05) (Fig.
2A). In 284 non-BA subjects, there was also signifi-
cant correlation between log PC20 and percentage of
sputum eosinophils (r = −0.219, P < 0.01) (Fig. 2B).
There was no correlation between log PC20 and per-
centage of sputum eosinophils in 11 CBA subjects
(data not shown).
DISCUSSION
Our study showed that young adults with long-term
remission of childhood asthma continued to have air-
way eosinophilic inflammation and bronchial hyperre-
sponsiveness, and the former asthma subjects had
narrowing of lower airways, including small airways.
It has been demonstrated that most subjects consid-
ered to be in asthma remission have a persistent in-
crease in airway responsiveness,5,6 airway obstruc-
tion,5 and eosinophilia in bronchoalveolar lavage
fluid,3 bronchial biopsy specimens4 and induced spu-
tum.8 To our knowledge, in most previous studies,
clinical remission of asthma was defined as reported
complete absence of asthma symptoms in subjects
not taking any asthma medications for only 1 to 3
years. On the other hand, Obase et al. defined clinical
remission of childhood asthma as free of asthma
symptoms for at least 10 years.8 Remission of asthma
remains unsolved13 and the duration of clinical remis-
sion of asthma is variable. In previous studies, it may
be possible that because durations of childhood
asthma remission were shorter, subjects with out-
grown asthma had eosinophilic airway inflammation
and bronchial hyperresponsiveness. Our results sug-
gest that the longer duration of remission of child-
hood asthma (i.e. 10 years) does not result in vanish-
ing of lower airway eosinophilic inflammation and air-
way hyperresponsiveness. This result may agree with
a previous report showing that there was no correla-
tion between airway responsiveness to methacholine
and duration of asthma remission.5
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The Japanese Pediatric Guidelines for The Treat-
ment and Management of Asthma 2005 define func-
tional remission of asthma as complete absence of
symptoms and no use of medication in the previous 5
years, and pulmonary function test and bronchial re-
sponsiveness are normal. These guidelines also de-
fine clinical remission of asthma as complete absence
of symptoms and no use of medication in the previ-
ous 5 years.14 In our study, 25.8% of subjects with
clinical remission of asthma, who had been free of
asthma symptoms and had not taken any asthma
medication, were considered to be in functional re-
mission. We could not investigate childhood factors
associated with adulthood asthma remission (i.e. pul-
monary functions in childhood). Vonk et al. showed
that remission was associated with a higher lung
function level in childhood and a higher subsequent
increase in FEV1.15 Furthermore, we could not follow
up subjects with clinical remission of asthma in this
study. Ongoing airway inflammation and bronchial
hyperresponsiveness may be risk factors for future
recurrence in subjects with clinical remission of
asthma.3,16
In our study, several non-BA subjects had bron-
chial hyperresponsiveness andor sputum eosino-
philia. 60 (18.4% of 326 subjects) non-BA subjects had
bronchial hyperresponsiveness in this study. It was
shown that 34% of Japanese university students with
atopy, without asthma, had bronchial hyperrespon-
siveness to methacholine (PC20 <8 mgmL).17 The
prevalence of bronchial hyperresponsiveness in the
general population varies from 4 to 35%.18 Asympto-
matic bronchial hyperresponsiveness in non-asthma
subjects is considered to be a risk factor for develop-
ing asthma in future.19-25 Though we did not investi-
gate neither personal nor familial allergic disease,
these two factors may contribute to the relationship
between bronchial hyperresponsiveness and develop-
ment of asthma.21-25 Several studies have analyzed in-
duced sputum17,26-28 and bronchial biopsy23 to investi-
gate airway inflammation in non-asthma subjects with
bronchial hyperresponsiveness. Airway eosinophils
in these subjects were higher than in non-asthma
subjects without bronchial hyperresponsiveness23,27
and were not different from those in asthma sub-
jects.26 The mechanism by which the asymptomatic
phase of bronchial hyperresponsiveness becomes
overt symptomatic asthma remains unclear, but the
associated increased inflammatory cell infiltrate may
play an important role in this phenomenon.
In our study, former asthma subjects had signifi-
cantly higher body weight and higher BMI than
those of non-asthma subjects. Cross-sectional epide-
miologic studies have indicated a modest association
between obesity and prevalence of asthma.29-32 A
meta-analysis of prospective epidemiologic studies
showed that asthma incidence increases by 50% in
overweight and obese individuals.33 This study also
demonstrated a dose-response relationship between
BMI and asthma, suggesting that asthma risk in-
creases further as body weight increases.33 The pre-
sent study may support the association between
asthma and obesity.
MMF was used to assess small airway function.34
Several studies showed that subjects with former
asthma had abnormal small airway functions.5,35-38
But, to the best of our knowledge, in those reports,
the periods of asthma remission were defined only
from 1 month to 2 years. Furthermore, in some re-
ports,5,35,38 subjects with a smoking history were not
excluded. In our study, subjects with asthma remis-
sion having no smoking history showed decreased
MMF compared with control subjects. Hamid et al.
demonstrated that similar but more severe inflamma-
tory and structural changes occurred in the small air-
ways of asthma subjects.39,40 Wagner et al. showed
that, in asthma subjects, the peripheral airway resis-
tance was increased up to sevenfold compared with
that of control subjects, and these measurements cor-
related with responsiveness to methacholine.41 Small
airways are considered to be predominant sites of air-
flow obstruction in asthma subjects.42 There is no evi-
dence suggesting that small airway remodeling is
present in subjects with asthma remission. Further-
more, it is unclear whether abnormality of small air-
ways in subjects with asthma remission could be a
target of medication as in asthma subjects. Koh et al.
demonstrated that 9 months of inhaled budesonide
could not cause a significant improvement in bron-
chial hyperresponsiveness to methacholine and FEV1
in adolescents with long-term asthma remission.43
Van den Toorn et al. found that 3 months of treat-
ment with a salmeterolfluticasone propionate combi-
nation could reduce airway hyperresponsiveness, ni-
tric oxide concentration in exhaled air and tryptase
density in the airway mucosa, but not major basic
protein, FEV1, FEV1 reversibility or quality of life of
subjects with remission of asthma.44 De Kluijver et al.
reported that repeated low-dose allergen exposure in
asymptomatic asthma subjects could lead to airway
inflammation without worsening of symptoms, which
could be prevented by inhaled budesonide treat-
ment.45 Whether prolonged anti-inflammatory treat-
ment alters the long-term prognosis in subjects with
remission of asthma remains to be determined by fu-
ture studies.
In conclusion, we found that former asthma sub-
jects, who had been free of symptoms and medica-
tions of childhood asthma for at least 10 years, had
eosinophilic airway inflammation, bronchial hyperre-
sponsiveness and airway narrowing. Long-term stud-
ies are needed to elucidate the necessity of interven-
tion and its efficacy and safety on airway inflamma-
tion, airway hyperresponsiveness and airway narrow-
ing in subjects with remission of asthma.
Hara J et al.
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